Maxigen Biotech (TPE:1783) Interest Expense : NT$0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Maxigen Biotech's interest expense for the three months ended in Mar. 2024 was NT$ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Maxigen Biotech's Operating Income for the three months ended in Mar. 2024 was NT$ 25.3 Mil. Maxigen Biotech's Interest Expense for the three months ended in Mar. 2024 was NT$ 0.0 Mil. Maxigen Biotech has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Maxigen Biotech Interest Expense Historical Data

The historical data trend for Maxigen Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech Interest Expense Chart

Maxigen Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-3.43

-0.25

-0.20

-0.07

Maxigen Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Maxigen Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

Maxigen Biotech (TPE:1783) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Maxigen Biotech's Interest Expense for the three months ended in Mar. 2024 was NT$0.0 Mil. Its Operating Income for the three months ended in Mar. 2024 was NT$25.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was NT$0.0 Mil.

Maxigen Biotech's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Maxigen Biotech had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Maxigen Biotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

Maxigen Biotech (TPE:1783) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333

Website

https://www.mbi.com.tw

Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech (TPE:1783) Headlines

No Headlines